{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:33:37Z","timestamp":1779910417050,"version":"3.53.1"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>The development of virus-like particle (VLP) based vaccines for human papillomavirus, hepatitis B and hepatitis E viruses represented a breakthrough in vaccine development. However, for dengue and COVID-19, technical complications, such as an incomplete understanding of the requirements for protective immunity, but also limitations in processes to manufacture VLP vaccines for enveloped viruses to large scale, have hampered VLP vaccine development. Selecting the right adjuvant is also an important consideration to ensure that a VLP vaccine induces protective antibody and T cell responses. For diseases like COVID-19 and dengue fever caused by RNA viruses that exist as families of viral variants with the potential to escape vaccine-induced immunity, the development of more efficacious vaccines is also necessary. Here, we describe the development and characterisation of novel VLP vaccine candidates using SARS-CoV-2 and dengue virus (DENV), containing the major viral structural proteins, as protypes for a novel approach to produce VLP vaccines. The VLPs were characterised by Western immunoblot, enzyme immunoassay, electron and atomic force microscopy, and <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> immunogenicity studies. Microscopy techniques showed proteins self-assemble to form VLPs authentic to native viruses. The inclusion of the glycolipid adjuvant, \u03b1-galactosylceramide (\u03b1-GalCer) in the vaccine formulation led to high levels of natural killer T (NKT) cell stimulation <jats:italic>in vitro<\/jats:italic>, and strong antibody and memory CD8<jats:sup>+<\/jats:sup> T cell responses <jats:italic>in vivo<\/jats:italic>, demonstrated with SARS-CoV-2, hepatitis C virus (HCV) and DEN VLPs. This study shows our unique vaccine formulation presents a promising, and much needed, new vaccine platform in the fight against infections caused by enveloped RNA viruses.<\/jats:p>","DOI":"10.3389\/fmicb.2023.1065609","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T05:47:25Z","timestamp":1686116845000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates"],"prefix":"10.3389","volume":"14","author":[{"given":"Simon","family":"Collett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Earnest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Carrera Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Edeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinn Yi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Mumford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Lecouturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Pavot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Keit","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivali A.","family":"Gulab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Elbourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Ramsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiraj","family":"Hans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale I.","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Torresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1021\/acschembio.7b00845","article-title":"Augmenting influenza-specific T cell memory generation with a natural killer T cell-dependent glycolipid\u2013peptide vaccine","volume":"12","author":"Anderson","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1128\/CVI.00500-13","article-title":"Dengue virus subverts the interferon induction pathway via NS2B\/3 protease-IkappaB kinase epsilon interaction","volume":"21","author":"Anglero-Rodriguez","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature18938","article-title":"Structural basis of potent Zika-dengue virus antibody cross-neutralization","volume":"536","author":"Barba-Spaeth","year":"2016","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.1016\/j.vaccine.2018.10.072","article-title":"Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature","volume":"36","author":"Boigard","year":"2018","journal-title":"Vaccine"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.15585\/mmwr.mm7044e1","article-title":"Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021","volume":"70","author":"Bozio","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/eji.201142064","article-title":"Virus-like particles induce robust human T-helper cell responses","volume":"42","author":"Braun","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/d41586-022-03445-6","article-title":"COVID 'variant soup' is making winter surges hard to predict","volume":"611","author":"Callaway","year":"2022","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5694\/mja2.50569","article-title":"Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia","volume":"212","author":"Caly","year":"2020","journal-title":"Med. J. Aust."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/imt.13.175","article-title":"Optimizing NKT cell ligands as vaccine adjuvants","volume":"6","author":"Carreno","year":"2014","journal-title":"Immunotherapy"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"679344","DOI":"10.3389\/fimmu.2021.679344","article-title":"From COVID-19 to cancer mRNA vaccines: moving from bench to Clinic in the Vaccine Landscape","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front. Immunol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1089\/vim.2017.0182","article-title":"Antibody responses to a quadrivalent hepatitis C viral-like particle vaccine adjuvanted with toll-like receptor 2 agonists","volume":"31","author":"Christiansen","year":"","journal-title":"Viral Immunol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1038\/s41598-018-24762-9","article-title":"Immunological responses following administration of a genotype 1a\/1b\/2\/3a quadrivalent HCV VLP vaccine","volume":"8","author":"Christiansen","year":"","journal-title":"Sci. Rep."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"9251","DOI":"10.1038\/s41598-019-45461-z","article-title":"Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery","volume":"9","author":"Christiansen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jcis.2019.03.022","article-title":"Probing and pressing surfaces of hepatitis C virus-like particles","volume":"545","author":"Collett","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jcis.2021.02.067","article-title":"Investigating virus\u2013host cell interactions: comparative binding forces between hepatitis C virus-like particles and host cell receptors in 2D and 3D cell culture models","volume":"592","author":"Collett","year":"2021","journal-title":"J. Colloid Interface Sci."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.4049\/jimmunol.171.8.4020","article-title":"Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells","volume":"171","author":"Crowe","year":"2003","journal-title":"J. Immunol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/CJI.0b013e31818f13c4","article-title":"Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes","volume":"32","author":"Cubas","year":"2009","journal-title":"J. Immunother."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"de Alwis","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cells"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"104574","DOI":"10.1016\/j.ebiom.2023.104574","article-title":"Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine","volume":"92","author":"Deliyannis","year":"2022","journal-title":"EBioMedicine"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.15.21267805","article-title":"Booster of mRNA-1273 vaccine reduces SARS-CoV-2 omicron escape from neutralizing antibodies","author":"Doria-Rose","year":"2021","journal-title":"medRxiv"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jviromet.2016.06.012","article-title":"Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine","volume":"236","author":"Earnest-Silveira","year":"","journal-title":"J. Virol. Methods"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1099\/jgv.0.000493","article-title":"Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line","volume":"97","author":"Earnest-Silveira","year":"","journal-title":"J. Gen. Virol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ebiom.2016.10.006","article-title":"Protective role of cross-reactive CD8 T cells against dengue virus infection","volume":"13","author":"Elong Ngono","year":"2016","journal-title":"EBioMedicine"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref36","volume-title":"Report 50: Hospitalisation risk for omicron cases in England","author":"Ferguson","year":"2021"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"Fibriansah","year":"2015","journal-title":"Science"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.1128\/JVI.00757-13","article-title":"Structural changes in dengue virus when exposed to a temperature of 37 degrees C","volume":"87","author":"Fibriansah","year":"2013","journal-title":"J. Virol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/emmm.201303404","article-title":"A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface","volume":"6","author":"Fibriansah","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e01461-15","DOI":"10.1128\/mBio.01461-15","article-title":"A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies","volume":"6","author":"Gallichotte","year":"2015","journal-title":"mBio"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/ni.3298","article-title":"The burgeoning family of unconventional T cells","volume":"16","author":"Godfrey","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1073\/pnas.0813309106","article-title":"Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity","volume":"106","author":"Guillonneau","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3390\/v2122649","article-title":"The complexity of antibody-dependent enhancement of dengue virus infection","volume":"2","author":"Guzman","year":"2010","journal-title":"Viruses"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England, multicentre prospective cohort study (the SIREN study)","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","article-title":"Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes","volume":"10","author":"Halstead","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 COVID-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"eaaz8035","DOI":"10.1126\/sciimmunol.aaz8035","article-title":"Glycolipid-peptide vaccination induces liver-resident memory CD+ T cells that protect against rodent malaria","volume":"5","author":"Holz","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.virol.2007.12.041","article-title":"A strong endoplasmic reticulum retention signal in the stem-anchor region of envelope glycoprotein of dengue virus type 2 affects the production of virus-like particles","volume":"374","author":"Hsieh","year":"2008","journal-title":"Virology"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"17542","DOI":"10.1038\/s41598-021-97038-4","article-title":"Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate","volume":"11","author":"Imagawa","year":"2021","journal-title":"Sci. Rep."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.vaccine.2015.11.061","article-title":"Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: a novel VLP prime-adenovirus boost strategy","volume":"34","author":"Kumar","year":"2016","journal-title":"Vaccine"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2022","journal-title":"Nat. Med."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00705-010-0734-9","article-title":"Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus","volume":"155","author":"Lazo","year":"2010","journal-title":"Arch. Virol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.vaccine.2006.09.068","article-title":"A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus","volume":"25","author":"Lazo","year":"2007","journal-title":"Vaccine"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1097-2765(02)00655-X","article-title":"Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis","volume":"10","author":"Lemberg","year":"2002","journal-title":"Mol. Cell"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.carres.2017.10.006","article-title":"NKT-cell glycolipid agonist as adjuvant in synthetic vaccine","volume":"452","author":"Liu","year":"2017","journal-title":"Carbohydr. Res."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40249-022-01032-5","article-title":"Impact of the national hepatitis B immunization program in China: a modeling study","volume":"11","author":"Liu","year":"2022","journal-title":"Infect. Dis. Poverty"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nsmb.1382","article-title":"Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins","volume":"15","author":"Lok","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination","volume":"225","author":"L\u00f3pez-Medina","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41577-019-0243-3","article-title":"Novel vaccine technologies for the 21st century","volume":"20","author":"Mascola","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1093\/emboj\/cdf414","article-title":"Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets","volume":"21","author":"McLauchlan","year":"2002","journal-title":"EMBO J."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12985-018-0970-2","article-title":"Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope","volume":"15","author":"Metz","year":"2018","journal-title":"Virol. J."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.virol.2016.06.022","article-title":"Enhancing dengue virus maturation using a stable furin over-expressing cell line","volume":"497","author":"Mukherjee","year":"2016","journal-title":"Virology"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2478\/s11534-011-0096-2","article-title":"Gwyddion: an open-source software for SPM data analysis","volume":"10","author":"Ne\u010das","year":"2012","journal-title":"Centr. Eur. J. Phys."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1128\/JVI.00457-12","article-title":"Structural analysis of hepatitis C virus core-E1 signal peptide and requirements for cleavage of the genotype 3a signal sequence by signal peptide peptidase","volume":"86","author":"Oehler","year":"2012","journal-title":"J. Virol."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1080\/21645515.2016.1160977","article-title":"The promise and challenge of epitope-focused vaccines","volume":"12","author":"Oscherwitz","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0005-2736(97)00275-7","article-title":"Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: IV. Fate of liposomes in regional lymph nodes","volume":"1370","author":"Oussoren","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamainternmed.2021.7382","article-title":"Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine","volume":"182","author":"Patalon","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1700737","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1365-2893.2009.01118.x","article-title":"Sequential processing of hepatitis C virus core protein by host cell signal peptidase and signal peptide peptidase: a reassessment","volume":"16","author":"Pene","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.virol.2004.12.036","article-title":"Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein","volume":"333","author":"Purdy","year":"2005","journal-title":"Virology"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/vaccines8010139","article-title":"Recent Progress on the versatility of virus-like particles","volume":"8","author":"Qian","year":"2020","journal-title":"Vaccines"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.chom.2022.11.012","article-title":"Enhanced neutralization resistance of SARS-CoV-2 omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2","volume":"31","author":"Qu","year":"2022","journal-title":"Cell Host Microbe"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1038\/s41598-018-26904-5","article-title":"Dengue envelope-based \u2018four-in-one\u2019 virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice","volume":"8","author":"Rajpoot","year":"2018","journal-title":"Sci. Rep."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e0006191","DOI":"10.1371\/journal.pntd.0006191","article-title":"A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice","volume":"12","author":"Ramasamy","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of COVID-19 mRNA vaccine against omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2021","journal-title":"Clin. Infect. Diseas."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/JVI.02675-12","article-title":"Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection","volume":"87","author":"Rivino","year":"2013","journal-title":"J. Virol."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/imm.12681","article-title":"CD4(+) and CD8(+) T-cell immunity to dengue - lessons for the study of Zika virus","volume":"150","author":"Rivino","year":"2017","journal-title":"Immunology"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","article-title":"Recurrent potent human neutralizing antibodies to zika virus in Brazil and Mexico","volume":"169","author":"Robbiani","year":"2017","journal-title":"Cells"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref88","article-title":"Limited cross-variant immunity after infection with the SARS-CoV-2 omicron variant without vaccination","author":"Suryawanshi","year":"2022","journal-title":"medRxiv"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1056\/NEJMc2211845","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2","volume":"87","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cells"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.virol.2012.08.037","article-title":"Characterization of cellular furin content as a potential factor determining the susceptibility of cultured human and animal cells to coronavirus infectious bronchitis virus infection","volume":"433","author":"Tay","year":"2012","journal-title":"Virology"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1101\/2022.11.22.22282629","article-title":"Continued emergence and evolution of omicron in South Africa: new BA.4 and BA.5 lineages","author":"Tegally","year":"2022","journal-title":"medRxiv"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"914167","DOI":"10.3389\/fimmu.2022.914167","article-title":"A complementary union of SARS-CoV-2 natural and vaccine induced immune responses","volume":"13","author":"Torresi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.4049\/jimmunol.175.5.3092","article-title":"NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge","volume":"175","author":"Uldrich","year":"2005","journal-title":"J. Immunol."},{"key":"ref95","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1473-3099(22)00816-7","article-title":"Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB","volume":"23","author":"Uraki","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13568-020-01087-3","article-title":"Production of dengue virus-like particles serotype-3 in silkworm larvae and their ability to elicit a humoral immune response in mice","volume":"10","author":"Utomo","year":"2020","journal-title":"AMB Express"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1126\/science.1070925","article-title":"Identification of signal peptide peptidase, a presenilin-type aspartic protease","volume":"296","author":"Weihofen","year":"2002","journal-title":"Science"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"eLife"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.4049\/jimmunol.1400065","article-title":"Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies","volume":"192","author":"Zabel","year":"2014","journal-title":"J. Immunol."},{"key":"ref104","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1406011","article-title":"Long-term efficacy of a hepatitis E vaccine","volume":"372","author":"Zhang","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1065609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T05:47:30Z","timestamp":1686116850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2023.1065609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":104,"alternative-id":["10.3389\/fmicb.2023.1065609"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2023.1065609","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"article-number":"1065609"}}